Haloperidol Krka (Haloperidol)

Haloperidol Krka is given by slow intravenous injection or infusion under medical supervision. The exact dosing regimen depends on the clinical indication, patient weight, and response, and should follow the prescribing information provided by the healthcare professional.

The medication is commonly used for schizophrenia, acute psychotic episodes, manic episodes of bipolar disorder, and severe agitation or aggression that requires rapid control.

Common adverse effects include drowsiness or sedation, extrapyramidal symptoms such as tremor, rigidity, or akathisia, and dry mouth or increased salivation.

Monitoring includes regular assessment of temperature, muscle rigidity, autonomic instability, and elevated creatine kinase levels. Early recognition and immediate discontinuation of haloperidol, along with supportive care, are essential.

The pregnancy safety profile is not well defined. Clinicians must weigh potential benefits against unknown risks and consider alternative therapies when possible.

Haloperidol can prolong the QT interval, increasing the risk of arrhythmias. Baseline and periodic ECG monitoring, correction of electrolyte abnormalities, and avoidance of other QT‑prolonging drugs help mitigate this risk.

Drugs that also block dopamine receptors, strong CYP3A4 inhibitors, and other agents known to prolong the QT interval should be avoided to reduce additive adverse effects.

CYP3A4 inhibitors can increase haloperidol plasma concentrations, potentially intensifying side effects such as sedation, extrapyramidal symptoms, and cardiac effects. Dose adjustments or alternative therapies may be required.

Clinicians should assess symptom severity, consider dose reduction, and may add anticholinergic agents (e.g., benztropine) or switch to a different antipsychotic. Ongoing monitoring is important.

Use in children is generally off‑label and should be limited to situations where benefits clearly outweigh risks, with careful dosing and monitoring.

By blocking D2 receptors in the mesolimbic pathway, haloperidol reduces excessive dopaminergic activity that underlies psychotic symptoms, thereby improving mood, thought organization, and behavior.